Erica N Boswell

TL;DR: Some of the specific challenges that present with each type of treatment and the socio-physical impact they have on survivorship are discussed and the contemporary literature is reviewed to determine effective management and treatment of sexual dysfunction.

TL;DR: In this article, the safety and activity of the histone deacetylase inhibitor panobinostat in patients with relapsed/refractory Waldenstrom macroglobulinemia (WM) were evaluated.

TL;DR: An initial attempt of a radiographic pattern-based approach to drug-related pneumonitis in the era of molecular targeting therapy is described, with a cohort of patients with Waldenström macroglobulinemia receiving mTOR inhibitor therapy as a paradigm, to contribute to further understanding and in-depth interpretation of lung toxicity during novel cancer therapy.

TL;DR: It is concluded that panobinostat is an active therapeutic agent in patients with relapsed/ refractory Waldenström macroglobulinemia and a role for histone deacetylase inhibitors as an active class of therapeutic agents in WM is established.

TL;DR: It is demonstrated that the combination of everolimus, bortezomib and rituximab is well tolerated and achieved 89% response rate even in patients previously treated, making it a possible model of non-chemotherapeutic-based combination therapy in WM.